Get started
Author

Linhui Peng

Observed name: L.-H. Peng
ORCID: 0009-0008-0916-4737
Observed ORCID: 0009-0008-0916-4737
OpenAlex ID: A5048211111
Immune Gene–Viral Therapy with Triplex Efficacy Mediated by Oncolytic Adenovirus Carrying an Interferon-γ Gene Yields Efficient Antitumor Activity in Immunodeficient and Immunocompetent Mice
2006 · Changqing Su, Linhui Peng, et al. · Molecular Therapy · 62
PDF
Increased Safety with Preserved Antitumoral Efficacy on Hepatocellular Carcinoma with Dual-Regulated Oncolytic Adenovirus
2006 · Qi Zhang, Guihua Chen, et al. · Clinical Cancer Research · 48
Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells
2004 · C.-Q. Su, J. Sham, et al. · Journal of Cancer Research and Clinical Oncology · 32
Serum CEA, CA125, CA19-9, and CA724 levels for the diagnosis and staging of cholangiocarcinoma
2017 · Yawen Deng, Rihui Zhong, et al. · Biomedical Research-tokyo · 5
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.
2024 · Xu Yunxiuxiu, Linhui Peng, et al. · Journal of Clinical Oncology · 4
Novel perspectives on combining immune checkpoint inhibitors and antiangiogenic drugs for advanced hepatocellular carcinoma
2025 · Linhui Peng · Oncology and Translational Medicine · 3
Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
2024 · Linhui Peng, Tao Chen, et al. · Journal of Clinical Oncology · 3
Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial.
2025 · Linhui Peng, Yajin Chen, et al. · Journal of Clinical Oncology · 1
PDF
Apatinib combined with adebrelimab and GEMOX regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A multicenter, open-label, single-arm, phase II trial.
2026 · Changzhen Shang, Dong Chen, et al. · Journal of Clinical Oncology
CAREFOL: A phase 3, randomized, open-label, multicenter trial of camrelizumab and rivoceranib with or without intravenous FOLFOX chemotherapy as first-line treatment for unresectable hepatocellular carcinoma.
2026 · Linhui Peng, Yajin Chen, et al. · Journal of Clinical Oncology
Economic evaluation of icaritin versus cinobufotalin for first-line treatment of unresectable hepatocellular carcinoma
2025 · Jie Zhao, Linhui Peng, et al. · Asian Journal of Surgery
TMEM88 modulates the proliferation and metastasis of HCC via the GSK-3β/β-catenin pathway
2025 · Jihao Zhang, Xi Chen, et al. · BMC Cancer
Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
2023 · Linhui Peng, Tao Chen, et al. · Journal of Clinical Oncology
A Novel Replication-competent Adenovirus CNHK500 in the Treatment of Heptocellular Carcinoma In Vitro
2004 · Qijun Qian, Qi Zhang, et al. · The Chinese-German Journal of Clinical Oncology
Works count: 14
Citation count: 158
H-index: 4
I10-index: 3
Year
Topic
Type